



## Inhibitions of Hepatitis C Virus Replication with the Help of CRISPR/Cas 9 Technology

Muhammad Umar Farooq<sup>1\*</sup> and Mehwish<sup>2</sup>

<sup>1</sup>Aziz Fatima Medical and Dental College, Pakistan

<sup>2</sup>Institute of Molecular Biology and Biotechnology, Bzu Multan, Pakistan

\*Corresponding Author: Muhammad Umar Farooq, Aziz Fatima Medical and Dental College, Pakistan.

Received: April 16, 2019; Published: May 08, 2019

### Abstract

Hepatitis c infection caused by Hepatitis c virus (HBV) is a major world-wide health problem. Current therapeutic strategies rarely eradicate HBV infections and fail to attain complete cure. There is urgent need to develop advanced treatment strategies to successfully remove HBV infection and eliminate hidden reservoirs of virus. Recently, the establishment of a novel RNA-guided gene editing tool known as the clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9 (CRISPR/Cas9) system, has significantly enabled site-specific mutagenesis and characterises a very beneficial possible therapeutic means for diseases which includes extermination of invasive pathogens e.g. HBV. This review highlights the recent developments in the use of CRISPR/Cas9 to specifically target HBV DNA sequences for inhibition of replication of HBV and to bring mutations in viral genome, animal models. Benefits, restrictions and viable solutions, and proposed guidelines for forthcoming study in CRISPR/Cas9 are described to highlight the chances and challenges for curative therapy of chronic hepatitis B infection.

**Keywords:** Hepatitis C Virus (HBV); Covalently Closed Circular DNA (cccDNA); CRISPR/Cas9; Inhibition of HBV Replication; Anti-viral Therapy

### Introduction

350 million persons are affected with hepatitis c virus (HBV) globally. Near about 10% of patients have chronic type of hepatitis c. Chronic hepatitis c (CHB) is a severe condition that may lead towards more critical symptoms like cirrhosis and hepatocellular carcinoma [1]. According to estimation 700 thousand patients infected with HBV develop chronic infection and died each year. From previous 20 years many antiviral therapies are in practice to suppress HBV infection but these are not effective to eliminate the infection [2]. HBV is member of Hepadnaviridae virus family and replicates inside the hepatocytes of human. The HBV genome contains DNA which is partially double-stranded [3]. It comprises of a complete coding strand and other is incomplete non-coding strand known as relaxed circular DNA (rcDNA) [4]. When virus infects hepatocytes, rcDNA from virus is transported towards the nucleus [5]. Where it is transformed into covalently closed circular

DNA (cDNA). cDNA works as the template for transcription of viral pregenomic RNA (pgRNA) and protein coding mRNAs [1]. After transcription viral transcripts are moved into the cytoplasm where these are translated into viral proteins. Then, the which consists of viral core and polymerase protein, reverse transcribe and form a new viral rcDNA [6]. Enveloped nucleocapsids which contains DNA secreted into cytoplasm as progeny virus or sometimes transported back to the nucleus for amplification of the cccDNA pool [7].

Present drugs against HBV include interferon- $\alpha$  (IFN- $\alpha$ ), nucleotide/nucleoside analogues used to adjust the immune response between host and virus [8]. Due to limited efficiency IFN- $\alpha$  cannot give in high dosage because patients cannot tolerate high dose. Although nucleoside analogues are used to control the infection but they cannot functionally cure HBV [9]. cccDNA is persistent, so long-term treatment required for patients, which is

expensive and develop drug resistance in patients [10]. HBV is a retrovirus, it can cause mutations during the reverse transcription which enhances their chance to be safe from removal by traditional antiviral drug treatment [11]. cccDNA have amazing stability and cannot disrupt by current antiviral therapies. More efficient and non-toxic methods are required for clearance of the cccDNA [12]. Recently, numerous new genome-editing methods have been developed, which based on sequence-specific endonucleases like zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and the most recent CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated 9) system [6]. The CRISPR/Cas9 system is basically natural defence mechanism of bacteria and archaea against virus. The Cas9 protein of type II CRISPR/Cas system has ability to cleave DNA at specific site with the help of CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA) [13]. PAM sequence (NGG) necessary for Cas9 protein to cleave the DNA. PAM sequence present downstream of the target DNA. It produces DNA breaks in double stranded DNA known as double strand breaks (DSBs). These DSBs are repaired by homologous direct repair mechanism or by non-homologous end-joining (NHEJ) repair mechanism [14]. The NHEJ mechanism is error-prone and can create insertions/deletions or other mutations during repair which cause frameshift mutations and ultimately gene knockout [15]. Moreover, there is also a chance that the crRNA-tracrRNA complex can be merged into a single guide RNA (gRNA) [16]. For cleavage CRISPR/Cas9 system needs a single strand that matches with the target DNA of virus. CRISPR/Cas9 system is convenient as compared to ZFN- and TALEN genome editing methods. That is recent advances in genome editing are based on the CRISPR/Cas9 system [17].

The gRNA-guided CRISPR/Cas9 (gRNA/Cas9) system has been effectively used in numerous areas of biological and medical sciences. This technique also has application in virus research, for example for the genome editing of Epstein-Barr virus and herpes simplex virus, and the abolition of human immunodeficiency virus (HIV) infection. This review provides the information that the gRNA/Cas9 system could greatly inhibit replication of HBV [17]. Inhibition can be *in vitro* and *in vivo* in which the viral genome directly disrupts by HBV specific gRNAs. Furthermore, HBV-specific gRNA/Cas9 systems can prevent the replications of HBV of different strains in cells. A single gRNA/Cas9 system can significantly reduce the viral genome and combination of different gRNA/Cas9 systems used to eliminate the persistent viral genome [18].

This review demonstrates the prospect to inhibit replication of virus and clearance of persistent cDNA of HBV that is used for functional anti-HBV therapy, reduce the drug resistance which occur due to mutations during replication [19]. One of the major advantage of CRISPR/Cas9 over other approaches for gene editing is that its capacity of multiplex targeting which provides a way for several disruptions, insertions, and deletions with greater efficiency and less cost. Thus, for improved destruction efficiency in the genome of HBV for multiple genomic editing, the blend of diverse site specific sgRNAs that can target several sequences will be perfect scheme [20].

**Materials and Methods**

Hepatitis C is a	Yes	No
1. Viral disease		
2. Bacterial disease		
3. Fungal disease		
4. Genetic disease		
5. Metabolic disease		
6. Ever suffered from Hepatitis C		
7. You		
8. Your family		
9. Your relative		
10. Your neighbor		
11. Your friend		
12. Hepatitis C is transmitted by		
13. Contacts or blood transfusion		
14. From parents to offspring		
15. Hepatitis C may be treated by		
16. Medicines		
17. Surgery		
18. Do not worry, it is easily curable		

**Table 1:** Questionnaire to evaluate awareness about etiology of Hepatitis C.

Hepatitis C is a	Yes	No
1. Viral disease		
2. Bacterial disease		
3. Fungal disease		
4. Genetic disease		
5. Metabolic disease		

**Table 2:** Questionnaire to evaluate awareness about etiology of Hepatitis A.

Ever suffered from Hepatitis C	Yes	No
1. You		
2. Your family		
3. Your relative		
4. Your neighbor		
5. Your friend		

**Table 3:** Questionnaire to evaluate views about prevalence of Hepatitis C.

Questionnaire to evaluate views about transmission of Hepatitis C

Hepatitis A is transmitted by	Yes	No
1. Contacts Table or blood transfusion		

**Table a**

Hepatitis C may be treated by	Yes	No
1. Medicines		
2. Surgery		
3. Do not worry, it is easily curable		

**Table 4:** Questionnaire to evaluate views about Hope for Hepatitis C.

## Results

Questions	Male		Female		Total	
	Yes	No	Yes	No	Yes	No
1. Viral disease	92%	8%	96%	4%	96%	4%
2. Bacterial disease	41%	59%	15%	85%	30%	70%
3. Fungal disease	70%	30%	73%	27%	30%	70%
4. Genetic disease	37%	63%	70%	30%	34%	74%
5. Metabolic disease	63%	37%	80%	20%	90%	10%

**Table 5:** Awareness about etiology of Hepatitis C: Views of Postgraduate Biology Students.

## Discussion

### Role of CRISPR/Cas9 to Target cDNA and inhibition of HBV replication

Genome of the HBV has four long open reading frames that are surface, core, polymerase, and X protein. These are translated into only seven proteins which are very important for replication of virus. For suppression of viral gene expression and replication, targeting any 1 of 7 proteins is enough. Many examples are present in which HBV genome is targeted with CRISPR/Cas9 system. A scientist reported that the CRISPR/Cas9 system can disrupt the viral genome both *in vitro* and *in vivo* [21]. Cas9/sgRNA specific for HBV can significantly decrease the construction of HBV core and surface antigen, when a complex of Cas9 and HBV expression plasmid transfected into carcinoma cells derived from Huh7 hepatocyte [22]. Moreover, CRISPR/Cas9 system efficiently decrease the intrahepatic HBV-expressing vectors level and surface antigen serum levels in an HBV infected mouse model [23]. Transduction of Cas9 and HBV-specific gRNAs by using lentiviral, effective inhibition of HBV DNA and cccDNA is observed [24]. According to a study levels of total HBV viral DNA decline up to ~1000-fold by the CRISPR/Cas9 and cccDNA level declines up to ~10-folds. According to Seeger and Sohn HBV contaminations can be repressed up to eightfold by HBV-specific guide RNAs in NTCP expressing HepG2 cells. In alternative study, Liu., *et al.* stated that HBV-specific gRNA/Cas9 can prevent the HBV replication of diverse genotypes equally *in vitro* and *in vivo*, it is due to removal and fallible repair of viral DNA templates [20]. This system can efficiently impede levels of HBV DNA and HBsAg countenance in liver of mouse. According to Dong., *et al.* the CRISPR/Cas system can be used for impeding intracellular cccDNA. Ramanan., *et al.* showed that sgRNAs targeting conserved regions of HBV cause strong inhibition of virus replication both *in vitro* and *in vivo*, and extended this antiviral activity to virus isolated from patients [25]. Continuous expression of Cas9/sgRNA shows rapid decline of persistent cccDNA and HBV proteins in a denovo infection model. Recently, Karimova., *et al.* demonstrated that an advanced CRISPR/Cas9 nickase system has capability to disturb both HBV cccDNA and fused HBV sequences in HeLa and HEK293 cell lines [26]. In short, these findings demonstrate the successfully use of the CRISPR/Cas9 system in destroying HBV cDNA both *in vitro* and *in vivo*, and shown the therapeutic approach of CRISPR/Cas9 in both acute and chronic HBV infection [27].

### Challenges for the CRISPR/Cas9 system as a Novel HBV therapeutic approach

Before clinical application of CRISPR/Cas9 systems for HBV treatment, significant problems are needed to be addressed. Major concern is related to capability of extermination of all viruses [28]. Yet, by Ramanan, *et al.* achieved the best result for cleavage of HBV via CRISPR/Cas9. The suppression of cDNA is about 92% in cultured cells. One of the major challenge is presence of HBV DNA in different tissues external the liver and replication of HBV in different cell lines [29]. To eradicate HBV, it is important that nucleases transported to every single infected cell in liver and outside the liver reservoirs of virus. For sustained *in vivo* anti-HBV action, an effective vehicle for delivery must be used [24].

Recombinant adeno-associated viral vectors (rAAVs) are considered as best delivering vehicle for CRISPR/Cas9 due to the less immune response, non incorporating nature, and high infection efficacy [30]. Packaging difficulty can be resolved by enchanting benefit of a split-Cas9 system or by means of a smaller Cas9 orthologs e.g. SaCas9 from *Staphylococcus aureus*, which is shorter than 1 kb [20]. The second issue of CRISPR/Cas9 system is the probable off-target effects. Previously published data show that the rate of off-target activity of CRISPR/Cas9 system is high, even in case of sgRNAs which have almost five nucleotides mismatches [26]. Numerous methods have been established to decrease off-target effects.

One approach is “paired nicking”. It reduces the off-target delivery by using two spaced gRNAs and a mutated Cas9 (Cas9n). Both can cleave single-strand DNA and instead of producing DSBs a nick is formed on both DNA strands. Nicks further repaired accurately by the cell repair mechanism. Paired nicking reduced off-target effect by 50–1,000 fold in cell lines comparing to the wild-type Cas9. 2<sup>nd</sup> strategy is the use of Truncate sgRNAs at the end of the complementary targeting sequence. Fu, *et al.* described that a short sgRNAs of 17 or 18 nucleotides may increase specificity for target sequence by more than 5000-fold without decreasing the on-target activity. fCas9 is another modified Cas9 which designed by fusing of catalytically inactive Cas9 and Fok I nuclease. Specificity of fCas9 system increased by 140-fold than normal Cas9 by increasing targeting sequences in human cells [31]. But, these methods remain less effective. Selection of appropriate target sites in the genome of HBV has greater concern. The main issue of Nucleoside/Nucleotide analogue therapy is the

occurrence of HB variants which are therapy-resistant. CRISPR/Cas9 system provides specific sequence recognition [27]. In case of high viral, the CRISPR/Cas9 provide a pool of therapy-resistant viruses which can re establish infection. So, overlapping of targeting sequence with regions like (Y)- methionine (M)-aspartic acid (D)-aspartic acid (D) (YMDD) motif should avoid. Importantly, due to high sequence deviation, genome of HBV is classified into eight genotypes A–H [32]. Use of multiple CRISPR/Cas9 constructs and targeting of highly conserved regions between diverse viral genotypes are good approaches for reducing the issue of current and de novo mutations [33]. Persistent incorporated linearized viral DNA, cleaves by the CRISPR/Cas9 system. The incorporation of sub genomic viral DNA parts into genome of host is common in hepatocellular carcinoma or chronically infected patients. Host gene function can be disrupted by cleavage of incorporated viral DNA which lead to insertion/deletion mutation in host genome. The undesirable side effects must be evaluated carefully [25].

### Potential Target for HBV in Gene Editing Therapy with CRISPR/Cas9

Different genome editing strategies have been currently used as tool against numerous human viruses. In curative HIV research field, studies presented that CD4+ T cells with chemokine (CC motif) receptor 5 (CCR5)-disturbed by nucleases show resistance against HIV-1 infection. ZFNs which disrupt CCR5 is under phase I clinical trials, is breakthrough [34]. Recently Sodium taurocholate co-transporting polypeptide identified as an entrance receptor of HBV and HDV which facilitates the transportation of bile acids and other molecules from portal circulation. One class of the indirect anti-HBV agents in progress are entrance inhibitors, which target the HBV receptor NTCP [35]. With the inspiring result of nucleases based CCR5 gene editing therapy, it stances to reason behind use of CRISPR/Cas9 for disruption of NTCP expression block the entrance of HBV and stop the spread of viral infection [36]. Yet again, although no reports of dangerous diseases linked with faults in the NTCP gene have been available yet, the possible modification of function of gene and NTCP disruption toxicity must be assessed [33].

### Conclusion

The CRISPR/Cas9 technology has enormously advanced our capability to edit and provides the new era of gene therapies for treatment of diseases.

Although it still in a clinical trial stage, CRISPR/Cas9 system used both *in vitro* and *in vivo* way for inhibition of HBV replication and gene expression, and may establish a new beneficial strategy for HBV infection. Currently use of combined CRISPR/Cas9 therapy and RT inhibitors may attain the maximum rates of viral response. Still many difficulties remain to evaluate including safety and effective delivery of the system, CRISPR/Cas9 strategies provide immense potential to cure chronic HBV infection. Experimental research has revealed that CRISPR/Cas9 cleaves episomal cccDNA, decreases pgRNA, and inhibit viral proteins without any cytotoxic effects, providing considerable evidence that CRISPR/Cas9 strategy is a promising tool with the possibility to work as an efficient HBV infections treatment and to exterminate cccDNA. But it is significant to be careful around the challenges that reduce the practicability and security of these innovative methods. Many problems should be resolved. Many improvements are required to achieve effective and safer therapeutic techniques to use CRISPR/Cas9 technology for eradication of cccDNA and inhibition of HBV.

## Bibliography

- Kennedy EM., *et al.* "Targeting hepatitis B virus ccc DNA using CRISPR/Cas9". *Antiviral Research* 123 (2015b): 188-192.
- Dienstag JL. "Hepatitis B virus infection". *New England Journal of Medicine* 359 (2008): 1486-1500.
- Gebbing M., *et al.* "A Gene therapeutic approaches to inhibit hepatitis B virus replication". *World Journal* 7 (2015): 150-164.
- Ayoub W and Keeffe E. "Current antiviral therapy of chronic hepatitis B". *Alimentary Pharmacology and Therapeutics* 34 (2011): 1145-1158.
- Mehvish S and Qadir M. "Gene therapy for hepatocellular carcinoma". *Rev Gene Therapy* 1 (2011): 11-21.
- Li H., *et al.* "Removal of integrated hepatitis B virus DNA using CRISPR-Cas9". *Frontiers in Cellular and Infection Microbiology* 7 (2017): 91.
- Peng C., *et al.* "CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV". *Virologica Sinica* 30 (2015): 317-325.
- Perz JF., *et al.* "The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide". *Journal of Hepatology* 45 (2006): 529-538.
- Schädler S and Hildt E. "HBV life cycle: entry and morphogenesis". *Viruses* 1 (2009): 185-209.
- Niaz M., *et al.* "Tumor markers for early detection of cancer". *Pharmacologyonline* 3 (2010): 628-633.
- Block TM., *et al.* "CL Chronic hepatitis B: a wave of new therapies on the horizon". *Antiviral Research* 121 (2015): 69.
- Kennedy EM., *et al.* "Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease". *Virology* 476 (2015a): 196-205.
- Lin G., *et al.* "Application of CRISPR/Cas9 technology to HBV". *International Journal of Molecular Sciences* 16 (2015): 26077-26086.
- Liu X., *et al.* "Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome". *Journal of General Virology* 96 (2015): 2252-2261.
- Qadir M. "Advances in treatment of lungs cancer". *Independent Review* 103 (2011): 176-180.
- Mei Y., *et al.* "Recent progress in CRISPR/Cas9 technology". *Journal of Genetics and Genomics* 43 (2016): 63-75.
- Moyo B., *et al.* "Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus". *Virus Research* (2017).
- Seeger C and Mason WS. "Molecular biology of hepatitis B virus infection". *Virology* 479 (2015): 672-686.
- Zhu W., *et al.* "The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA". *Retrovirology* 12 (2015): 22.
- Seeger C and Sohn JA. "Targeting hepatitis B virus with CRISPR/Cas9". *Molecular Therapy-Nucleic Acids* 3 (2014).
- Saayman S., *et al.* "The therapeutic application of CRISPR/Cas9 technologies for HIV". *Expert Opinion on Biological Therapy* 15 (2015): 819-830.

22. Schiffer JT, *et al.* "Targeted DNA mutagenesis for the cure of chronic viral infections". *Journal of Virology* 86 (2012): 8920-8936.
23. Zhen S., *et al.* "Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus". *Gene therapy* 22 (2015): 404.
24. Schweitzer A., *et al.* "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013". *The Lancet* 386 (2015): 1546-1555.
25. Kennedy EM., *et al.* "Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic". *Methods* 91 (2015c): 82-86.
26. Shalem O., *et al.* "Genome-scale CRISPR-Cas9 knockout screening in human cells". *Science* 343 (2014): 84-87.
27. Shen B., *et al.* "Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects". *Nature methods* 11 (2014): 399.
28. Hai H., *et al.* "Role of hepatitis B virus DNA integration in human hepatocarcinogenesis". *World Journal of Gastroenterology* 20 (2014): 6236.
29. Kennedy EM and Cullen BR. "Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment". *Virology* 479 (2015): 213-220.
30. Yin H., *et al.* "Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype". *Nature Biotechnology* 32 (2014): 551.
31. Xu T., *et al.* "Cas9-based tools for targeted genome editing and transcriptional control". *Applied and Environmental Microbiology* 80 (2014): 1544-1552.
32. Yang H-C and Kao J-H. "Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance". *Emerging Microbes and Infections* 3 (2014): e64.
33. Komatsu H. "Hepatitis B virus: where do we stand and what is the next step for eradication?" *World Journal of Gastroenterology* 20 (2014): 8998.
34. Wyman C and Kanaar R. "DNA double-strand break repair: all's well that ends well". *Annual Review of Genetics* 40 (2006): 363-383.
35. Yan H., *et al.* "Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide". *Journal of Virology* 87 (2013): 7977-7991.
36. Yang H., *et al.* "One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering". *Cell* 154 (2013): 1370-1379.

**Volume 3 Issue 6 June 2019**

**© All rights are reserved by Muhammad Umar Farooq and Mehwish.**